The estimated Net Worth of Barry Buckland is at least $136 Thousand dollars as of 11 June 2024. Barry Buckland owns over 11,793 units of Dyadic International stock worth over $48,709 and over the last 5 years he sold DYAI stock worth over $0. In addition, he makes $87,000 as Independent Director at Dyadic International.
Barry has made over 3 trades of the Dyadic International stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 11,793 units of DYAI stock worth $18,751 on 11 June 2024.
The largest trade he's ever made was exercising 27,174 units of Dyadic International stock on 2 January 2024 worth over $33,968. On average, Barry trades about 6,746 units every 206 days since 2019. As of 11 June 2024 he still owns at least 38,967 units of Dyadic International stock.
You can see the complete history of Barry Buckland stock trades at the bottom of the page.
Dr. Barry C. Buckland Ph.D. serves as Independent Director of the Company. Barry Buckland, Ph.D. joined the Board in January 2018. Dr. Buckland retired from Merck Research Laboratories in 2009 after 28 years of contributions to the Bioprocess R&D group including more than 12 years as leader in the position of Vice President. Since leaving the Merck Research Laboratories, Dr. Buckland has headed up his own consulting company (BiologicB, LLC). He also is President of Engineering Conferences International (ECI), a not for profit organization which organizes prestigious conferences with an engineering focus. Dr. Buckland has chaired successful conference such as Microbial Engineering I and Vaccine Technology Conferences I to IV. He is also a visiting professor at University College London in the Biochemical Engineering Department and is the author or co-author of more than 70 publications. His previous board experience includes Enumeral Biomedical and Mucosis. Dr. Buckland was a Senior Advisor to Protein Sciences until they were purchased by Sanofi in 2017. Dr. Buckland became Executive Director of NIIMBL (National Institute for Innovation for
As the Independent Director of Dyadic International, the total compensation of Barry Buckland at Dyadic International is $87,000. There are 10 executives at Dyadic International getting paid more, with Mark Emalfarb having the highest compensation of $1,074,050.
Barry Buckland is 72, he's been the Independent Director of Dyadic International since 2018. There are 1 older and 10 younger executives at Dyadic International. The oldest executive at Dyadic International, Inc. is Jack Kaye, 76, who is the Independent Director.
Barry's mailing address filed with the SEC is C/O DYADIC INTERNATIONAL, INC., 1044 NORTH U.S. HIGHWAY ONE, SUITE 201, JUPITER, FL, 33477-5094.
Over the last 6 years, insiders at Dyadic International have traded over $118,246,658,250 worth of Dyadic International stock and bought 27,000 units worth $100,230 . The most active insiders traders include Mark A Emalfarb, Ronen Tchelet, and Seth Herbst. On average, Dyadic International executives and independent directors trade stock every 73 days with the average trade being worth of $54,365. The most recent stock trade was executed by Barry Buckland on 11 June 2024, trading 11,793 units of DYAI stock currently worth $18,751.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Dyadic International executives and other stock owners filed with the SEC include: